inter observer variability of a subjective predictor like DRE and DRE assessed volume. The slight differences in DRE findings between the two urologists had very little impact on the performance of the RPCRC. The DRE-based RPCRC can be considered a useful Bx outcome prediction tool.
INTRODUCTION AND OBJECTIVES: Chemoprevention of prostate cancer has long been an interesting topic. Data have shown that Metformin is associated with lower prostate specific antigen levels. A recent study showed that Metformin can modify gene expression in prostate cancer cells. Literature is controversial on the role of metformin in prostate cancer prevention. This study was designed to assess relationship of diabetes mellitus and metformin with prostate cancer.
METHODS: A database of patients with prostate cancer was searched for patients with diabetes mellitus taking medications. Patients with diabetes mellitus prior to prostate cancer detection were detected. Data were imported into SPSS v. 21 for analysis. After primary analysis, patients taking metformin were compared to diabetic patients not taking metformin and non-diabetic patients.
RESULTS: Between March 2003 and October 2016, there were 3,645 patients in the database of which 228 (6.2%) were diagnosed with diabetes mellitus prior to the time of prostate cancer detection. In diabetic group, 139 patients were using metformin products prior to surgery. There were additional 35 patients who were taking metformin for other conditions rather than diabetes mellitus. A general comparison of characteristics of diabetic and non-diabetic patients in the study is shown in table 1. Diabetic patients were more commonly black, had higher BMI, Higher D'Amico risk and higher American Society of Anesthesiologist risk classification (all p<0.05). There was no significant difference between diabetic patients taking metformin and diabetic patients on other treatment plans. Analysis of patients taking metformin with other patients (diabetic and non-diabetic) showed no significant difference in terms of prostate cancer characteristics.
CONCLUSIONS: Diabetes mellitus might impact the course of prostate cancer development. The results of the study does not support the protective effect of metformin on prostate cancers in diabetic or nondiabetic. 
Source of Funding: None

INTRODUCTION AND OBJECTIVES:
The ERSPC risk calculator estimates the risk of positive prostate biopsy. We aimed at evaluating whether the inclusion of mpMRI data might improve the predictive accuracy of this calculator in detecting positive biopsy in patients undergoing mpMRI targeted biopsy.
METHODS: 214 consecutive patients underwent mpMRI of the prostate with subsequent targeted and concomitant systematic biopsy at a single centre between 2013 and 2016. A 1.5 T mpMRI study using an endorectal coil was performed in all patients who had also complete data required by ERSPC risk calculator 4. Four multivariable logistic regression analyses (MVA) were performed to assess the predictors of positive biopsy. Predictors included in Model 1 were those of the ERSPC risk calculator, namely transrectal ultra-sonography (normal vs. abnormal), digital rectal examination (normal vs. abnormal), prostate volume (ml), the logarithmic transformation of PSA (ng/ml), previous negative biopsy (no vs. yes). Model 2 included as predictor only by PIRADS v.2 (<4 vs. !4). Predictors of Model 3 and Model 4 were the same of Model 1 plus PIRADS (<4 vs. !4) for Model 3 and PIRADS (<4 vs. !4) + patient age for Model 4. Leave-one-out cross validation (LOOCV) and calibration plots were used to internally validate each model. Decision curve analyses (DCA) were performed to evaluate and compare the net benefit associated with the use of each model. RESULTS: Overall, 63% had a positive biopsy. At MVA of Model 1, prostate volume (OR: 0.97) and PSA (OR: 2.8), were independent predictors of positive biopsy (all p 0.001). In all models including mpMRI results (Model 2-4), the presence of PIRADS !4 was significantly associated with positive biopsy (OR range: 3-4.6; all p 0.001). At MVA of Model 3 and 4, prostate volume and PSA also reached the independent predictor status for positive biopsy prediction (all p 0.009). Moreover, at MVA of Model 4, older age was significantly associated with positive biopsy (OR: 1.08, p<0.001). In LOOCV, inclusion of age and mpMRI results into the ERSPC risk 4 calculator was associated with the highest accuracy (C-index 77.3%) as compared to all other models tested (Cindex of model 1, 2, 3: 65.8 vs. 53.7 vs. 73.7%, respectively). At DCA, the combined use of age, mpMRI and ERSPC calculator resulted into higher net-benefit relative to all the other 3 Models.
CONCLUSIONS: Our data demonstrated the importance of inclusion of both PIRADS v.2 and patient age into the ERSPC risk calculator to better identify patients with higher risk of positive biopsy. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1027 on AS must undergo PSA testing and repeated biopsies over time in all proposed protocols and patients are subjected to discomfort and anxiety as well as to the complications of repeated biopsies. We tried to identify the predictors of progression-free survival (PFS) at a single institution AS program in order to identify patients in whom repeated biopsies could be avoided or reduced in frequency. METHODS: Between 2009 and 2016, 235 consecutive patients affected by low-risk PCa according to PRIAS criteria (cT1/T2a; PSA<10 ng/ml; PSA density <0.2; Gleason score <7; <3 positive cores) were enrolled in our AS program. Tumor progression was defined as pathological upgrading (Gleason >6 or >2 positive cores) at repeated yearly biopsies. First, Kaplan-Meier analyses were used to quantify progression-free survival at 1, 3 and 5 years, respectively. Second, we identified patients who were progression-free at 3 years of follow-up. Finally, univariable and multivariable logistic regression analyses were used to predict 3-year PFS. Covariates consisted of age, total PSA, clinical stage (cT) and number of positive cores at the time of enrolment as well as negative (no cancer) 1-year biopsy.
Source of
RESULTS: Progression-free survival rate was 85%, 55%, and 40% at 1, 3 and 5 years, respectively. Median follow-up was 19 months. Overall, 56 (23.8%) patients were progression-free at 3 years of followup. Median number of cores at enrolment in AS program was 16 (IQR: 14-20), while median number of cores at first-year biopsy was 18 (IQR: 14-20). At univariable analyses, total PSA and negative 1-year biopsy were significant predictors of 3-year PFS (all p<0.05). Patients with negative biopsy at 1 year had a 3-year PFS of 75.8 vs. 29.0% in those with positive biopsy at 1-year. These results were confirmed at multivariable analyses, where a negative 1-year biopsy represented the only independent predictor of 3-year PFS (OR: 2.47; p¼0.04).
CONCLUSIONS: The first biopsy after enrolment in AS program is an important predictor of PCa progression in the first 3 years in men on AS. Negative findings at 1-year biopsy suggest a high chance of 3-year PFS. Patients with negative 1-year biopsy could be followedup with less stringent biopsy protocol, in order to reduce possible biopsy-related side effects and discomfort. 
INTRODUCTION AND OBJECTIVES:
The optimal interval between prostate biopsy and radical prostatectomy (RP) is unknown. Therefore we sought to determine the impact of time from biopsy to surgery on outcomes following RP.
METHODS: 13,265 men who underwent RP at our institution between 1992 and 2012 had a prostate biopsy within one year of surgery. Men were divided into four groups based on the interval between biopsy and surgery: 1) 3 weeks (n¼2511), 2) 4-6 weeks (n¼2493), 3) 7-12 weeks (n¼5273), 4) >12 weeks (n¼2998) to assess for complications. Oncologic outcomes were compared between those waiting 3 weeks (n¼2511) versus !6 months (n¼443), stratified by NCCN risk category. Logistic regression was performed to assess the impact of time on postoperative complications, functional and oncologic outcomes.
RESULTS: Mean time from biopsy to surgery was 63 days (AE51 days) and the overall complication rate for the cohort was 19.8% with a 1.0% intraoperative complication rate. Men undergoing RP within 3 weeks of biopsy were older (63.4 vs 61.7; p<0.001), with higher preoperative PSA (9.1 vs 7.6; p<0.001) and clinically higher risk disease (3.2% vs 1.9% with !2 NCCN high risk criteria; p<0.001) compared to those who waited more than 12 weeks until surgery. On multivariate analysis, waiting at least 7 weeks was associated with a lower likelihood of complications (OR: 0.8, p¼ 0.01) and higher likelihood of a nerve sparing procedure (OR: 1.6, p<0.001). Men waiting 12 weeks were least likely to have a positive margin (OR: 0.6, p<0.001). There was no significant difference in functional outcomes at 1 year. Finally, there was no clinically significant difference in oncologic outcomes among men undergoing early ( 3 weeks) compared to delayed (!6 months) RP.
CONCLUSIONS: Waiting at least 6 weeks from biopsy to RP is associated with a lower overall complication and positive margin rate. There appears to be no oncologic harm in waiting 6-12 months between biopsy and RP, even for men with intermediate and high risk disease.
Source of Funding: none
MP77-18 WHAT FALSE NEGATIVE RATE OF NON-INVASIVE TESTING ARE ACTIVE SURVEILLANCE PATIENTS AND URO-ONCOLOGISTS WILLING TO ACCEPT IN ORDER TO AVOID PROSTATE BIOPSY?
INTRODUCTION AND OBJECTIVES: Repeat prostate biopsies in active surveillance patients are associated with significant complications. Novel imaging and blood/urine based non-invasive tests are being developed to better predict disease grade and volume progression. We conducted a theoretical study to determine what test performance characteristics and costs would a non-invasive test(s) require in order for patients and their physicians to comfortably avoid biopsy.
METHODS: Surveys were administered to two populations to determine an acceptable false-negative rate and cost for such test(s). AS patients were recruited at time of visit to the prostate cancer clinic at Princess Margaret Cancer Centre, beginning August 2015 for a period of four months. Responses from urologic oncologists worldwide were obtained in March 2016 by circulating an online survey via the Society of Urologic Oncology. Participants were questioned about their demographics and other characteristics that might influence chosen error rates and cost. Differences between patient and physician choices were tested using the Chi-square test.
RESULTS: 136 patients and 670 physicians were surveyed, with 130 (96%) and 104 (16%) responses obtained, respectively. 90.6% of patients were comfortable with a non-invasive test(s) in place of biopsy, with 64.8% accepting a false-negative rate of 5% or worse. 25.8% of patients requested a FN rate of 1% or lower. 93.3% of physicians were comfortable with a non-invasive test, with 77.9% accepting a rate of 5% or worse. 15.4% of physicians requested a FN rate of 1% or lower. 75% of patients and 77% of physicians felt that a cost of less than $1,000, per administration, would be reasonable. No significant differences existed between patient and physicians choices for FN rate or costs (p>0.05).
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